Glucocerebrosidase

Structure

β-Glucocerebrosidase is a member of the glycoside hydrolase family 30 and consists of three distinct domains (I-III). File:Structure of human beta-glucocerebrosidase @.png|Three-dimensional PyMol rendering of glucocerebrosidase with three domains highlighted. File:Glucocerebrosidase active site.png|Three-dimensional PyMol rendering of glucocerebrosidase with catalytic residues highlighted. Domain I (residues 1–27 and 383–414) forms a three-stranded anti-parallel β-sheet. This domain contains two disulfide bridges that are necessary for correct folding, as well as a glycosylated residue (Asn19) that is required for catalytic activity in vivo. Domain II (residues 30–75 and 431–497) consists of two β-sheets that resemble an immunoglobulin fold. Domain III (residues 76–381 and 416–430) is homologous to a TIM barrel and is a highly conserved domain among glycoside hydrolases. Domain III harbors the active site, which binds the substrate glucocerebroside in close proximity to the catalytic residues E340 and E235. Domains I and III are tightly associated, while domains II and III are joined by a disordered linker.

Mechanism

Crystal structures indicate that β-glucocerebrosidase binds the glucose moiety and adjacent O-glycosydic bond of glucocerebroside. The two aliphatic chains of glucocerebroside may remain associated with the lysosomal bilayer or interact with the activating protein Saposin C.

Consistent with other glycoside hydrolases, the mechanism of glucocerebroside hydrolysis by β-glucocerebrosidase involves acid/base catalysis by two glutamic acid residues (E340 and E235) and precedes through a two-step mechanism. In the first step, E340 performs a nucleophilic attack at the carbon of the O-glycosidic linkage to displace the sphingosine moiety, which is simultaneously protonated by E235 as it is released from the active site. In the second step, glucose is hydrolyzed from the E340 residue to regenerate the active enzyme.

Properties

β-Glucocerebrosidase is maximally active at pH 5.5, the pH of the lysosomal compartment. Within the lysosome it remains associated with the membrane, where it binds and degrades its substrate glucocerebroside (GluCer). It requires the activating protein Saposin C as well as negatively charged lipids for maximal catalytic activity. The role of Saposin C is not known; however, it is shown to bind both the lysosomal membrane and the lipid moieties of GluCer, and therefore may recruit GluCer to the active site of the enzyme.

β-Glucocerebrosidase is specifically and irreversibly inhibited by the glucose analog Conduritol B epoxide. Conduritol B epoxide binds to the GCase active site, where the enzyme cleaves its epoxide ring, forming a permanent covalent bond between the enzyme and the inhibitor.

Initially, GCase was thought to be one of the few lysosomal enzymes that does not follow the mannose-6-phosphate pathway for trafficking to the lysosome. A study in I-cell disease fibroblasts (in which the phosphotransferase that puts Mannose 6-phosphate on proteins to target them to the lysosome is defective) showed targeting of GCase to the lysosome independent of the M6P pathway. The lysosomal transporter and integral membrane protein LIMP-2 (Lysosomal Integral Membrane Protein 2) was shown to bind GCase and facilitate transport to the lysosome, demonstrating a mechanism for M6P-independent lysosomal trafficking. This conclusion was called into question when a crystal structure of GCase in complex with LIMP-2 showed a Mannose 6-phosphate moiety on LIMP-2, suggesting the complex can also follow the traditional mannose-6-phosphate pathway.

Clinical significance

Mutations in the glucocerebrosidase gene cause Gaucher's disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides in macrophages that infiltrate many vital organs.

Mutations in the glucocerebrosidase gene are also associated with Parkinson's disease.

A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants encoding the same protein.

Drugs

Alglucerase (Ceredase) was a version of glucocerebrosidase that was harvested from human placental tissue and then modified with enzymes. It was approved by the FDA in 1991 but has been withdrawn from the market due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue. Drugs made recombinantly pose no risk of diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture.

Recombinant glucocerebrosidases used as drugs include:

• Imiglucerase (Cerezyme)
• Velaglucerase (Vpriv)
• Taliglucerase alfa (Elelyso)

References

References

1. (November 2001). "Localization of ceramide and glucosylceramide in human epidermis by immunogold electron microscopy". The Journal of Investigative Dermatology.
2. (March 1991). "Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells". The Journal of Biological Chemistry.
3. (2011). "A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C". Enzyme Research.
4. (June 2003). "Identification and analysis of catalytic TIM barrel domains in seven further glycoside hydrolase families". FEBS Letters.
5. (August 2001). "Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate". Nature.
6. (April 2006). "Secretion of human glucocerebrosidase from stable transformed insect cells using native signal sequences". Biochemistry and Cell Biology.
7. (October 1990). "Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease". Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.
8. (April 1995). "Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase". Protein Science.
9. (October 2006). "Direct visualization of saposin remodelling of lipid bilayers". Journal of Molecular Biology.
10. (July 2012). "The role of saposin C in Gaucher disease". Molecular Genetics and Metabolism.
11. (June 1999). "Synthesis and evaluation of glucocerebrosidase inhibitory activity of anhydro deoxyinositols from (+)-epi- and (-)-vibo-quercitols". Bioorganic & Medicinal Chemistry Letters.
12. (November 2007). "LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase". Cell.
13. (October 1993). "Mannose 6-phosphate-independent targeting of lysosomal enzymes in I-cell disease B lymphoblasts". The Journal of Cell Biology.
14. (July 2014). "Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor". Nature Communications.
15. (2015). "Pathogenesis of Bone Alterations in Gaucher Disease: The Role of Immune System". Journal of Immunology Research.
16. (February 2017). "A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments". International Journal of Molecular Sciences.
17. (August 2015). "Parkinson's disease". Lancet.
18. PhD, Lindsey Shapiro. (2023-09-18). "Researchers win Breakthrough Prize for Parkinson's genetics discoveries {{!}} Parkinson's News Today".
19. "Entrez Gene: GBA glucosidase, beta; acid (includes glucosylceramidase)".
20. (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Design, Development and Therapy.
21. (1991). "Regulatory Matters". WHO Drug Information.
22. (2014-08-08). "Enzyme-replacement Therapy for Lysosomal Storage Disorders". Aetna.
23. (March 2012). "FDA Prescription and Over-the-Counter Drug Product List". U.S. Food and Drug Administration.
24. (2012). "Gaucher disease and other storage disorders". Hematology. American Society of Hematology. Education Program.
25. Yukhananov, Anna. (1 May 2012). "U.S. FDA approves Pfizer/Protalix drug for Gaucher". [[Chicago Tribune]].